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Abstract: The increased mortality reported with intensive glycaemic control has been attributed
to an increased risk of treatment-related hypoglycaemia. This study investigated the relationships
of haemoglobin (Hb) A1c, anti-hyperglycaemic treatment, and potential risks of adverse effects
with all-cause mortality in patients with type 2 diabetes. Patients (n = 15,773) were stratified into
four categories according to baseline HbA1c and then assigned to three target categories, based on
whether HbA1c was ≤0.5% below or above (on-target), >0.5% below (below-target) or >0.5% above
(above-target) their HbA1c goal, personalized according to the number of potential risks among age
> 70 years, diabetes duration > 10 years, advanced complication(s), and severe comorbidity (ies).
The vital status was retrieved for 15,656 patients (99.26%). Over a 7.4-year follow-up, mortality risk
was increased among patients in the highest HbA1c category (≥8.5%) (adjusted hazard ratio, 1.34 (95%
confidence interval, 1.22–1.47), p < 0.001) and those above-target (1.42 (1.29–1.57), p < 0.001). Risk
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was increased among individuals in the lowest HbA1c category (<6.5%) and those below-target only
if treated with agents causing hypoglycaemia (1.16 (1.03–1.29), p = 0.01 and 1.10 (1.01–1.22), p = 0.04,
respectively). These data suggest the importance of setting both upper and lower personalized
HbA1c goals to avoid overtreatment in high-risk individuals with type 2 diabetes treated with agents
causing hypoglycaemia.
Keywords: type 2 diabetes; HbA1c all-cause mortality; adverse treatment effects; hypoglycaemia
1. Introduction
The impact of strict glycaemic control on excess morbidity and mortality from cardiovascular
disease (CVD) in individuals with type 2 diabetes is still a matter of debate [1]. Indeed, the post-trial
follow-up of the United Kingdom Prospective Diabetes Study (UKPDS) showed a significant reduction
of macrovascular outcomes, together with the persistence of microvascular benefits, in patients
originally randomized to intensive treatment, thus supporting the need for strict glycaemic control
since the early stage of the disease [2]. Conversely, other landmark intervention trials designed to
achieve more ambitious glycaemic targets, the Action to Control Cardiovascular Risk in Diabetes
(ACCORD) [3], the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled
Evaluation (ADVANCE) [4], and the Veterans Affairs Diabetes Trial (VADT) [5], were successful in
reducing the burden from microvascular disease, but failed to detect significant effects on the primary
composite CVD outcome. In addition, in the intensive treatment arm, the ACCORD reported an
increase in all-cause and CVD mortality, which led to the anticipated end of the trial [3], whereas the
VADT showed a non-significant increment of the death rate [5]. These contrasting results have been
related to differences in patients’ baseline clinical features between the UKPDS and the other three
trials, i.e., newly diagnosed versus longstanding type 2 diabetes, younger versus older age, better
versus worse glycaemic control, and low versus high CVD risk [6,7].
Altogether, the above findings prompted a substantial paradigm shift in glycaemic targets for
patients with type 2 diabetes, moving from “one size fits all” to “personalized goals”. As a consequence,
the recommended haemoglobin (Hb) A1c level of <7.0% for all individuals was changed to HbA1c values
ranging from <6.5% to <8.5%, based on the presence and extent of several factors which may render
the patient vulnerable to aggressive treatment, thus decreasing the benefits and increasing the harm
from intensive glycaemic control [8]. The factors to be considered include age/life expectancy, disease
duration, established complications, important comorbidities, risks associated with hypoglycaemia,
individual attitude and expected treatment efforts, and resources and support systems.
However, the increased all-cause and CVD mortality reported among the ACCORD (and VADT)
participants assigned to the intensive treatment group remains poorly understood. The extent
(and velocity) of HbA1c reduction from baseline and the rate of severe hypoglycaemia were higher
in the intensive arms of the ACCORD and VADT than in other trials [6,7], thus prompting the
hypothesis that the increased mortality was attributable to hypoglycaemic episodes associated with
(rapid) achievement of more stringent HbA1c targets in vulnerable individuals. However, although
severe hypoglycaemia was associated with increased mortality, the risk of death associated with severe
hypoglycaemia was relatively greater in the standard than in the intensive group of the ACCORD [9],
ADVANCE [10], and VADT [11]. In addition, a post hoc analysis of the ACCORD trial showed that
higher, not lower average HbA1c was associated with greater risk of death, which was higher with the
intensive than with the standard strategy only when average HbA1c was >7.0% and when little or
no decrease in HbA1c followed treatment initiation [12]. These findings suggest that patients with
the smaller response on glycaemic control and, hence, with persistently higher HbA1c requiring more
aggressive treatment, including insulin, are those at higher risk of hypoglycaemia and death, pointing
to a more complex relationship among hypoglycaemia, achieved HbA1c, and treatment intensity.
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This study aimed to investigate the relationships of on-treatment HbA1c levels, type of
anti-hyperglycaemic treatment, and potential risks of adverse treatment effects with all-cause mortality
in individuals with type 2 diabetes. To this end, we analysed the data from participants in the Renal
Insufficiency and Cardiovascular Events (RIACE) Italian Multicentre Study, who were evaluated at
baseline in the years 2006–2008, when the recommended HbA1c target was <7.0% for all patients.
2. Materials and Methods
2.1. Design
The RIACE is an observational, prospective, multicentre, cohort study on the impact of estimated
glomerular filtration rate (eGFR) on morbidity and mortality in patients with type 2 diabetes [13].
The study was conducted in accordance with the Declaration of Helsinki. It was approved by the
locally appointed ethics committees, and participants gave informed consent. Trial Registration:
NCT00715481; www.ClinicalTrials.gov.
2.2. Subjects
The study population included 15,773 Caucasian patients (after excluding 160 individuals with
missing or implausible values), consecutively attending 19 hospital-based, tertiary referral Diabetes
Clinics of the National Health Service throughout Italy (see Supplementary Materials) in the years
2006–2008. Exclusion criteria were dialysis or renal transplantation. Traditional CVD risk factors and
complications were determined as part of the baseline assessment using a standardized protocol across
participating centres [13].
2.3. All-Cause Mortality
The vital status of study subjects on 31 October 2015 was verified by interrogating the Italian
Health Card database (http://sistemats1.sanita.finanze.it/wps/portal/), which provides updated and
reliable information on all current Italian residents [14].
2.4. Traditional Cardiovascular Disease (CVD) Risk Factors
The study subjects underwent a structured interview in order to collect the following information:
age at the time of the interview, smoking status, known diabetes duration, co-morbidities, and current
glucose-, lipid-, and blood pressure (BP)-lowering therapy [13].
Body mass index (BMI) was calculated from weight and height. Waist circumference was measured
in 4618 subjects and estimated in the remaining 11,155 individuals from the log-transformed BMI
values, as previously described [15]. BP was measured with a sphygmomanometer with the patients
seated with the arm at the heart level.
HbA1c was measured by high-performance liquid chromatography (HPLC) using Diabetes
Control and Complications Trial (DCCT)-aligned methods; triglycerides and total and high-density
lipoprotein (HDL) cholesterol were determined in fasting blood samples by colorimetric enzymatic
methods; non-HDL cholesterol was calculated by the formula: total cholesterol–HDL cholesterol;
and low-density lipoprotein (LDL) cholesterol was calculated by the Friedewald formula. HbA1c
variability was calculated for each patient as the intra-individual standard deviation (HbA1c-SD) of
3-to-5 (4.52 ± 0.76) HbA1c values obtained in 8252 individuals from 9 centres during the 2-year period
preceding recruitment, including the enrolment visit [14].
2.5. Complications
The presence of diabetic kidney disease (DKD) was assessed by measuring albuminuria and
serum creatinine, as previously detailed [13,16]. Albumin excretion rate was obtained from 24-h urine
collections or calculated from the albumin-to-creatinine ratio in early-morning, first-voided urine
samples, using a conversion formula developed in patients with type 1 diabetes and preliminarily
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validated in a subgroup of RIACE participants. Albuminuria was measured in fresh urine samples
by immunonephelometry or immunoturbidimetry, in the absence of interfering clinical conditions.
One-to-three measurements for each patient were obtained; in cases of multiple measurements,
the geometric mean of 2–3 values was used for analysis. In individuals with multiple measurements,
the concordance rate between the first value and the geometric mean was >90% for all albuminuria
categories [16]. Serum (and urine) creatinine was measured by the modified Jaffe method and eGFR
was calculated by the Chronic Kidney Disease Epidemiology Collaboration equation [13]. Patients were
then classified into Kidney Disease: Improving Global Outcomes categories of albuminuria (A1 to A3)
and eGFR (G1 to G5) and assigned to one of the following DKD phenotypes: no DKD (i.e., A1G1-A1G2),
albuminuria alone (albuminuric DKD with preserved eGFR, i.e., A2G1-A2G2-A3G1-A3G2), reduced
eGFR alone (non-albuminuric DKD, i.e., A1G3-A1G4-A1G5), or both albuminuria and reduced eGFR
(albuminuric DKD with reduced eGFR, i.e., A2G3-A2G4-A2G5-A3G3-A3G4-A3G5), as previously
reported [13].
In each centre, the presence of diabetic retinopathy (DR) was assessed by an expert ophthalmologist
by dilated fundoscopy. Patients with mild or moderate non-proliferative DR were classified as having
non-advanced DR, whereas those with severe non-proliferative DR, proliferative DR, or maculopathy
were grouped into the advanced DR category. DR grade was assigned based on the worse eye [17].
Previous major acute CVD events, including myocardial infarction; stroke; foot ulcer/
gangrene/amputation; and coronary, carotid, and lower limb revascularization, were adjudicated based
on hospital discharge records by an ad hoc committee in each centre [18].
2.6. Categorization of Patients
Patients were stratified into the following HbA1c categories according to their baseline HbA1c
value: <6.5% (C1); 6.5–7.49% (C2); 7.5–8.49% (C3); and ≥8.5% (C4).
In addition, patients were arbitrarily assigned the following personalized HbA1c goals: <6.5% (G0);
<7.0% (G1); <7.5% (G2); <8.0% (G3); and <8.5% (G4). HbA1c goal were personalized according to the
number of potential risks of treatment adverse effects among age > 70 years; known diabetes duration >
10 years; presence of advanced complication(s), i.e., advanced DKD (eGFR < 30 mL/min/1.73 m2 and/or
macroalbuminuria) and/or advanced DR (severe non-proliferative, proliferative, or maculopathy) and/or
history of major acute CVD event(s) (myocardial infarction, stroke, foot ulcer/gangrene/amputation,
and coronary, carotid and lower limb revascularization); the presence of severe comorbidity(ies)
(chronic obstructive pulmonary disease, chronic liver disease and/or cancer). Specifically, the HbA1c
goal was set at <6.5% if none of above risks was present (G0) and was increased by 0.5% for each of
these four risks (i.e., from <7.0% (G1), if only one was present, to <8.5% (G4), if all four were present).
Patients were then assigned to three target categories, based on whether their baseline HbA1c
value was ≤0.5% below or above (on-target, T1), >0.5% below (below-target, T2), or >0.5% above
(above-target, T3) their personalized HbA1c goal.
Finally, patients from each HbA1c category (C1–C4) or target category (T1–T3) were further
classified based on whether they (a) were treated with anti-hyperglycaemic drugs causing
hypoglycaemia (n = 9830), i.e., insulin and/or insulin secretagogues (sulfonylureas or glinides),
either alone or combined with other anti-hyperglycaemic drugs, or (b) were not treated with these
agents (n = 5826) and were either on lifestyle measures only (n = 2123, 36.4%), i.e., diet and physical
activity, or receiving drugs not causing hypoglycaemia (n = 3703, 63.6%), i.e., acarbose, pioglitazone
and/or metformin, the latter taken by the vast majority of these individual (97.3%).
The distribution of patients according to personalized HbA1c goals and target categories is
reported in Table S1.
2.7. Statistical Analysis
Data are expressed as mean ± standard deviation (SD) or median (interquartile range),
for continuous variables, and number of cases (percentage), for categorical variables. Comparisons
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among groups were performed by one-way analysis of variance (ANOVA) or Kruskal–Wallis test,
according to the parametric or non-parametric distribution of continuous variables, followed by
Bonferroni correction or Mann–Whitney test, respectively, for post-hoc comparisons, and by Pearson’s
χ2 test for categorical variables.
Kaplan–Meier survival curves for all-cause mortality were calculated according to both HbA1c
categories (C1–C4) and target categories (T1–T3). Differences in survival rates were analysed using the
log-rank statistic. Survival analyses were performed by Cox proportional hazards regression according
to HbA1c categories and target categories using C2 and T1, respectively, as reference category. Analyses
by HbA1c categories were adjusted for baseline age and gender (model 1), age and gender plus CVD
risk factors, i.e., smoking habits, diabetes duration, BMI, triglycerides, total and HDL cholesterol,
lipid-lowering treatment, systolic and diastolic BP, and anti-hypertensive treatment (model 2), and age,
gender, and CVD risk factors plus complications, i.e., DKD phenotypes, DR grade, history of major
acute CVD events, and comorbidities (model 3). Analyses by HbA1c target categories were adjusted
for gender and the CVD risk factors smoking habits, BMI, triglycerides, total and HDL cholesterol,
lipid-lowering treatment, systolic and diastolic BP, anti-hypertensive treatment (model 1), and gender,
the above CVD risk factors, and the factors considered for patients’ stratification into target categories,
i.e., age, diabetes duration, complications, and comorbidities (model 2). In the subgroup of patients
with 3-to-5 HbA1c values obtained during the 2-year period before enrolment, all the above models were
also adjusted for HbA1c-SD. In addition, the above analyses were conducted separately for individuals
treated or not with agents causing hypoglycaemia and further dividing patients not on these agents in
those treated with lifestyle measures only and those on drugs not causing hypoglycaemia. The results
of these analyses were expressed as hazard ratios (HRs) and their 95% confidence intervals (CIs).
All p values were two-sided, and a p < 0.05 was considered statistically significant. Statistical
analyses were performed using SPSS version 13.0 (SPSS Inc., Chicago, IL, USA).
3. Results
Valid information on vital status was retrieved for 15,656 patients (99.26% of the original cohort).
At the time of the census, 12,054 (76.99%) patients were alive, whereas 3602 (23.01%) patients were
deceased; the follow-up duration was 7.42 ± 2.05 years [19].
The baseline clinical features by HbA1c categories are reported in Table 1 and Table S2. The general
HbA1c goal of <7.0% was met by 6287 participants (40.2%), whereas 3645 (23.3%) patients achieved the
more stringent HbA1c goal of <6.5%. Individuals in the lowest HbA1c category were younger and more
frequently males, had lower diabetes duration and prevalence of complications and a more favourable
CVD risk profile, and were less frequently current smokers and on anti-hyperglycaemic, lipid-lowering,
and anti-hypertensive treatment (including therapy with agents causing hypoglycaemia) than those in
the other HbA1c categories (Table 1). In each HbA1c category, age, diabetes duration, and prevalence of
complications/comorbidities were higher, whereas the lipid and BP profiles were better in patients who
were on agents causing hypoglycaemia than in those who were not (Table S2). Kaplan–Meier estimates
(Figure S1A), and unadjusted HRs (Figure 1A) for all-cause mortality increased with increasing HbA1c
category, with similar values for C1 and C2; after adjustment for age and gender and further adjustment
for CVD risk factors and complications/comorbidities, the HR for C3 became progressively similar to
those of C1 and C2, whereas that for C4 remained significantly higher (Figure 1B–D). The same trend
was observed among patients not treated with agents causing hypoglycaemia (Figure S1B and Table 2).
Conversely, among those on treatment with these drugs, Kaplan-Meier estimates and unadjusted
and adjusted HRs were highest in individuals in the lowest (C1) and highest (C4) HbA1c categories
(Figure S1B and Figure 2) and the HRs remained significantly higher versus the reference category C2
after adjustment for all confounders in both C1 and C4 (1.16 (1.03–1.29), p = 0.01, and 1.25 (1.13–1.39),
p < 0.001, respectively). When analysed separately, mortality risk was higher in patients on insulin
(alone or in combination) than in those on insulin secretagogues in each HbA1c category, whereas
it was not increased in patients treated with agents not causing hypoglycaemia and falling in the
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lowest HbA1c category, as compared with those on lifestyle measures only. Inclusion of HbA1c-SD as a
covariate in model 3 showed that HbA1c variability was independently associated with an increased
mortality risk (1.30 (1.20–1.40), p < 0.001, and 1.26 (1.19–1.36), p < 0.001, without and with patients’
stratification for type of anti-hyperglycaemic treatment, respectively), but the HRs for HbA1c categories
and HbA1c target categories were not affected.
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Variables C1 C2 C3 C4 p-Value 
N (%) 3645 (23.3) 5081 (32.5) 3608 (23.0) 3322 (21.2)  
Deaths, n (%) 737 (20.2) 1049 (20.6) 858 (23.8) 958 (28.8) <0.001 
Age, years 65.6 ± 10.6 67.1 ± 9.9 67.1 ± 10.2 66.3 ± 10.8 <0.001 
Male gender, n (%) 2233 (57.1) 2903 (55.9) 2018 (52.6) 1748 (56.9) <0.001 
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Triglycerides, mmol·L−1 1.46 ± 0.94 1.49 ± 0.85 1.56 ± 0.89 1.84 ± 1.27 <0.001 
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Non-HDL cholesterol, mmol L−1 2.78 ± 0.84 2.79 ± 0.83 2.76 ± 0.82 2.83 ± 0.90 <0.001 
Systolic BP, mmHg 136.3 ± 17.5 137.9 ± 17.7 139.6 ± 18.2 138.6 ± 18.7 <0.001 
Diastolic BP, mmHg 79.0 ± 9.4 78.6 ± 9.2 78.9 ± 9.5 78.7 ± 9.7 0.16 
Figure 1. Mortality risk by HbA1c categories. Cox proportional hazards regression according to HbA1c
categories, unadjusted (A) and adjusted for age and gender (B), plus cardiovascular disease (CVD) risk
factors (C), plus complications/comorbidities (D). HRs (95% CI) for mortality are shown for each HbA1c
category. HbA1c = haemoglobin A1c; HR = hazard ratio; CI = confidence interval; C1 = HbA1c <6.5%;
C2 = HbA1c 6.5%–7.49%; C3 = HbA1c 7.5%–8.49%; C4 = HbA1c ≥8.5%; ref*, the asterisk indicates the
reference category.
Table 1. Baseline clinical features of study participants by HbA1c categories.
Variables C1 C2 C3 C4 p-Value
N (%) 3645 (23.3) 5081 (32.5) 3608 (23.0) 3322 (21.2)
Deaths, n (%) 737 (20.2) 1049 (20.6) 858 (23.8) 958 (28.8) <0.001
Age, years 65.6 ± 10.6 67.1 ± 9.9 67.1 ± 10.2 66.3 ± 10.8 <0.001
Male gender, n (%) 2233 (57.1) 2903 (55.9) 2018 (52.6) 1748 (56.9) <0.001
Smoking, n (%) <0.001
Never 021 ( 5.4) 2850 (56.1) 2090 (57.9) 1 88 (56.8)
Former 107 (30.4) 1472 (29.0) 960 (26.6) 868 (26.1)
Current 517 (14.2) 759 (14.9) 558 (15.5) 566 (17.0)
Diabetes duration, years .0 ± 8.9 12.5 ± 9.9 15.7 ± 10.1 16.1 ± 1 2 <0.001
HbA1c, % .93 ± 0.46 6.97 ± 0.29 7.93 ± 0.28 9.77 ± 1.31 <0.001
(mmol·mol−1) 1.3 ± 5.0) (52.7 ± 3.2) (6 .2 ± 3.1) (83.3 ± 14.3)
BMI, kg·m−2 28.6 ± 4.9 28.6 ± 4.9 29.1 ± 5.2 29.7 ± 5.5 <0.001
Waist circumference, cm 101.8 ± 10.0 101.9 ± 10.0 102.7 ± 10.6 104.0 ± 11.1 <0.001
Triglycerides, mmol·L−1 1.46 ± 0.94 1.49 ± 0.85 1.56 ± 0.89 1.84 ± 1.27 <0.001
Total cholesterol, mmol L−1 4.74 ± 0.96 4.77 ± 0.95 4.75 ± 0.96 4.89 ± 1.09 <0.001
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Table 1. Cont.
Variables C1 C2 C3 C4 p-Value
HDL cholesterol, mmol·L−1 1.31 ± 0.36 1.31 ± 0.35 1.28 ± 0.34 1.24 ± 0.35 <0.001
LDL cholesterol, mmol L−1 3.43 ± 0.92 3.46 ± 0.91 3.47 ± 0.92 3.65 ± 1.05 0.01
Non-HDL cholesterol, mmol L−1 2.78 ± 0.84 2.79 ± 0.83 2.76 ± 0.82 2.83 ± 0.90 <0.001
Systolic BP, mmHg 136.3 ± 17.5 137.9 ± 17.7 139.6 ± 18.2 138.6 ± 18.7 <0.001
Diastolic BP, mmHg 79.0 ± 9.4 78.6 ± 9.2 78.9 ± 9.5 78.7 ± 9.7 0.16
Pulse pressure, mmHg 57.3 ± 15.3 59.3 ± 15.6 60.8 ± 16.0 60.0 ± 15.8 <0.001
Anti-hyperglycaemic treatment, n (%)
Lifestyle 1017 (27.9) 762 (15.0) 192 (5.3) 142 (4.3) <0.001
Insulin 440 (12.1) 913 (18.0) 1062 (29.4) 1509 (45.4) <0.001
Non-insulin agents 2188 (60.0) 3406 (67.0) 2354 (65.2) 1671 (50.3) <0.001
Metformin 1746 (47.9) 2840 (55.9) 2206 (61.1) 1853 (55.8) <0.001
Pioglitazone 87 (2.4) 167 (3.3) 163 (4.5) 137 (4.1) <0.001
Acarbose 36 (1.0) 43 (0.8) 47 (1.3) 44 (1.3) 0.09
Sulfonylureas 820 (22.5) 1677 (33.0) 1472 (40.8) 1281 (38.6) <0.001
Repaglinide 335 (9.2) 537 (10.6) 371 (10.3) 282 (8.5) 0.01
Agents causing hypoglycaemia, n (%) 1538 (42.2) 2944 (57.9) 2646 (73.3) 2702 (81.3) <0.001
Lipid-lowering treatment, n (%) 1572 (43.1) 2389 (47.0) 1728 (47.9) 1549 (46.6) <0.001
Anti-hypertensive treatment, n (%) 2509 (68.8) 3611 (71.1) 2601 (72.1) 2351 (70.8) <0.001
Albuminuria, mg·day−1 53.8 ± 225.5 68.7 ± 373.2 74.4 ± 329.7 96.0 ± 293.1 <0.001
Serum creatinine, µmol·L−1 81.3 ± 38.0 80.4 ± 35.4 80.4 ± 31.8 82.2 ± 31.8 0.27
eGFR, mL·min−1·1.73 m−2 81.6 ± 21.0 80.3 ± 20.1 79.9 ± 20.5 79.2 ± 22.6 <0.001
DKD phenotype, n (%) <0.001
No DKD 2554 (70.1) 3385 (66.6) 2269 (62.9) 1776 (53.5)
Albuminuric DKD with preserved eGFR 532 (14.6) 877 (17.3) 691 (19.2) 866 (26.1)
Non-albuminuric DKD 321 (8.8) 465 (9.2) 360 (10.0) 330 (9.9)
Albuminuric DKD with reduced eGFR 238 (6.5) 354 (7.0) 288 (8.0) 350 (10.5)
DR, n (%) <0.001
No DR 3178 (87.2) 4185 (82.4) 2658 (73.7) 2168 (63.5)
Non-advanced DR 242 (6.6) 503 (9.9) 586 (16.2) 616 (18.5)
Advanced DR 225 (6.2) 393 (7.7) 364 (10.1) 538 (16.2)
CVD, n (%)
Any 699 (19.2) 1086 (21.4) 906 (25.1) 929 (28.0) <0.001
Myocardial infarction 354 (9.7) 514 (10.1) 445 (12.3) 429 (12.9) <0.001
Coronary revascularization 295 (8.1) 487 (9.6) 411 (11.4) 386 (11.6) <0.001
Stroke 126 (3.5) 143 (2.8) 118 (3.3) 126 (3.8) 0.09
Carotid revascularization 120 (3.3) 240 (4.7) 235 (6.5) 261 (7.9) <0.001
Ulcer/gangrene/amputation 92 (2.5) 167 (3.3) 131 (3.6) 166 (5.0) <0.001
Lower limb revascularization 65 (1.8) 135 (2.7) 121 (3.4) 129 (3.9) <0.001
Comorbidities, n (%)
Any 682 (18.7) 872 (17.2) 620 (17.2) 613 (18.5) 0.15
COPD 173 (4.7) 201 (4.0) 142 (3.9) 158 (4.8) <0.001
Chronic liver disease 299 (8.2) 415 (8.2) 326 (9.0) 321 (9.7) 0.06
Cancer 279 (7.7) 342 (6.7) 215 (6.0) 195 (5.9) <0.001
HbA1c = haemoglobin A1c; C1 = HbA1c <6.5%; C2 = HbA1c 6.5–7.49%; C3 = HbA1c 7.5–8.49%; C4 = HbA1c ≥8.5%;
BMI = body mass index; HDL = high-density lipoprotein; LDL = low-density lipoprotein; BP = blood pressure;
ACE-I = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; eGFR = estimated glomerular
filtration rate; DKD = diabetic kidney disease; DR = diabetic retinopathy; CVD = cardiovascular disease; COPD =
chronic obstructive pulmonary disease.
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Figure 2. Mortality risk by HbA1c categories and use of agents causing hypoglycaemia. Cox proportional
hazards regression according to HbA1c categories among participants treated with agents causing
hypoglycaemia, unadjusted (A) and adjusted for age and gender (B), plus CVD risk factors (C),
plus complications/comorbidities (D). HRs (95% CI) for mortality are shown for each HbA1c category.
HbA1c = haemoglobin A1c; HR = hazard ratio; CI = confidence interval; C1 = HbA1c < 6.5%;
C2 = HbA1c 6.5–7.49%; C3 = HbA1c 7.5–8.49%; C4 = HbA1c ≥ 8.5%.
As expected, the great majority of participants (75.4%) had at least one potential risk (age≥ 70 years:
38.7%; diabetes duration > 10 years: 50.3%; presence of advanced complication (s): 32.0%; and presence
of severe comorbidity (ies): 17.8%) and, hence, were assigned to a higher HbA1c goal. The baseline
clinical features by HbA1c target categories are reported in Table 3 and Table S3. Participants with
above-target HbA1c values were 6,046 (38.6%), whereas the remaining 9610 patients (61.4%) achieved
their personalized HbA1c goal; however, of them, 4989 (31.9%) were on-target, whereas 4621 (29.5%)
were below-target, i.e., showed HbA1c values > 0.5% lower than their personalized goal. As expected,
individuals who were below-target had a higher prevalence of potential risks (especially older age
and higher prevalence of complications/comorbidities) and, hence, were more frequently assigned the
highest personalized HbA1c goals (i.e., <7.5% or higher, G2–G4), than both on-target and above-target
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patients (59.6% versus 40.7% and 37.0%, respectively) (Table S1). In addition, below-target individuals
were more frequently males and less frequently on insulin and agents causing hypoglycaemia and
showed a better CVD risk profile than above-target patients (Table 3). In each HbA1c target category,
potential risks, i.e., age, diabetes duration, and prevalence of complications/comorbidities, were higher
in patients who were on agents causing hypoglycaemia than in those who were not (Table S3).
Kaplan–Meier estimates (Figure S1C) and unadjusted HRs (Figure 3A) for all-cause mortality were
lowest in patients on-target, intermediate in those above-target, and highest in those below-target.
The increased risk in below-target individuals was progressively attenuated by adjustment for CVD
risk factors and potential risks, whereas it became significantly elevated in above-target patients
(Figure 3B,C). All the other covariates included in model 3 were significantly associated with mortality,
except BMI and systolic BP, and sensitivity analysis showed that, among potential risks, age had
the highest weight. The same trend was observed among patients not treated with agents causing
hypoglycaemia (Figure S1D and Table 4). Conversely, among patients on treatment with these drugs,
the increased risk of death versus the reference category T1 remained after adjustment for CVD risk
factors and potential risks in both T2 (1.10 (1.01–1.22), p = 0.04) and T3 (1.20 (1.09–1.32), p < 0.001)
individuals. Again, when analysed separately, mortality risk was higher in individuals on insulin
(alone or in combination) than in those on insulin secretagogues in each HbA1c target category and was
not increased in patients treated with agents not causing hypoglycaemia and falling in the below-target
category, as compared with those on lifestyle measures only. Results did not change when including
HbA1c-SD among the covariates or when HbA1c goals were personalized using different cut-offs for
age (>75 years) and diabetes (>15 years).
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Diabetes duration, years 12.7 ± 10.1 13.3 ± 10.7 13.6 ± 9.8 <0.001 
HbA1c, % 7.13 ± 0.57 6.22 ± 0.66 8.90 ± 1.40 <0.001 
(mmol·mol−1) (54.4 ± 6.2) (44.5 ± 7.2) (73.8 ± 15.3)  
BMI, kg·m−2 28.8 ± 5.0 28.2 ± 4.7 29.7 ± 5.5 <0.001 
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Figure 3. Mortality risk by HbA1c target categories and use of agents causing hypoglycaemia.
Cox proportional hazards regression according to HbA1c target categories in the whole cohort (A–C)
and among participants treated with agents causing hypoglycaemia (D–F), unadjusted (A,D) and
adjusted for CVD risk factors (B,E), complications/comorbidities (C,F). HRs (95% CI) for mortality are
shown for each HbA1c target category. HbA1c = haemoglobin A1c; HR = hazard ratio; CI = confidence
interval; T1 = HbA1c on-target (≤0.5% below or above personalized goal); T2 = HbA1c below-target
(>0.5% below personalized goal); T3 = HbA1c above-target (>0.5% above personalized goal).
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Table 3. Baseline clinical features of study participants by HbA1c target categories.
Variables T1 T2 T3 p-Value
n (%) 4989 (31.9) 4621 (29.5) 6046 (38.6)
Deaths, n (%) 991 (19.9) 1330 (28.8) 1281 (21.2) <0.001
Age, years 66.7 ± 9.9 69.4 ± 10.1 64.4 ± 10.3 <0.001
Male gender, n (%) 2833 (56.8) 2818 (61.0) 3251 (53.8) <0.001
Smoking, n (%) <0.001
Never 2837 (56.9) 2581 (55.9) 3431 (56.7)
Former 1435 (28.8) 1455 (31.5) 1517 (25.1)
Current 717 (14.4) 585 (12.7) 1098 (18.2)
Diabetes duration, years 12.7 ± 10.1 13.3 ± 10.7 13.6 ± 9.8 <0.001
HbA1c, % 7.13 ± 0.57 6.22 ± 0.66 8.90 ± 1.40 <0.001
(mmol·mol−1) (54.4 ± 6.2) (44.5 ± 7.2) (73.8 ± 15.3)
BMI, kg·m−2 28.8 ± 5.0 28.2 ± 4.7 29.7 ± 5.5 <0.001
Waist circumference, cm 102.1 ± 10.1 101.1 ± 9.7 103.9 ± 11.0 <0.001
Triglycerides, mmol·L−1 1.51 ± 0.89 1.42 ± 0.86 1.74 ± 1.14 <0.001
Total cholesterol, mmol·L−1 4.78 ± 0.95 4.69 ± 0.96 4.86 ± 1.04 <0.001
HDL cholesterol, mmol·L−1 1.30 ± 0.34 1.32 ± 0.37 1.26 ± 0.35 <0.001
LDL cholesterol, mmol·L−1 3.47 ± 0.91 3.37 ± 0.91 3.61 ± 1.00 <0.001
Non-HDL cholesterol, mmol·L−1 2.79 ± 0.82 2.73 ± 0.83 2.83 ± 0.88 <0.001
Systolic BP, mmHg 138.3 ± 17.9 137.5 ± 17.9 138.2 ± 18.2 0.06
Diastolic BP, mmHg 79.0 ± 9.2 78.3 ± 9.5 78.9 ± 9.6 0.01
Pulse pressure, mmHg 59.4 ± 15.6 59.2 ± 15.8 59.3 ± 15.7 0.87
Anti-hyperglycaemic treatment, n (%)
Lifestyle 810 (16.2) 927 (20.1) 376 (6.2) <0.001
Insulin 972 (19.5) 860 (18.6) 2092 (34.6) <0.001
Non-insulin agents 3207 (64.3) 2834 (61.3) 3578 (59.2) <0.001
Metformin 2784 (55.8) 2195 (47.5) 3666 (60.6) <0.001
Pioglitazone 181 (3.6) 92 (2.0) 281 (4.6) <0.001
Acarbose 49 (1.0) 47 (1.0) 74 (1.2) 0.41
Sulfonylureas 1610 (32.3) 1314 (28.4) 2326 (38.5) <0.001
Repaglinide 461 (9.2) 510 (11.0) 554 (9.2) 0.01
Agents causing hypoglycaemia, n (%) 2835 (56.8) 2557 (55.3) 4438 (73.4) <0.001
Lipid-lowering treatment, n (%) 2314 (46.4) 2148 (46.5) 2776 (45.9) 0.82
Anti-hypertensive treatment, n (%) 3504 (70.2) 3449 (74.6) 4119 (68.1) <0.001
Albuminuria, mg·day−1 64.1 ± 285.4 80.3 ± 377.0 73.0 ± 290.3 0.04
Serum creatinine, µmol·L−1 79.6 ± 31.8 85.7±42.4 78.7±29.2 <0.001
eGFR, mL·min−1·1.73 m−2 81.0±19.7 76.6±21.7 82.5±21.0 <0.001
DKD phenotype, n (%) <0.001
No DKD 3348 (67.1) 2859 (61.9) 3777 (62.5)
Albuminuric DKD with preserved eGFR 863 (17.3) 767 (16.6) 1336 (22.1)
Non-albuminuric DKD 461 (9.2) 523 (11.3) 492 (8.1)
Albuminuric DKD with reduced eGFR 317 (6.4) 472 (10.2) 441 (7.3)
DR, n (%) <0.001
No DR 4064 (81.5) 3695 (80.0) 4430 (73.3)
Non-advanced DR 529 (10.6) 444 (9.6) 974 (16.1)
Advanced DR 396 (7.9) 482 (10.4) 642 (10.6)
CVD, n (%)
Any 1004 (20.1) 1457 (31.5) 1159 (19.2) <0.001
Myocardial infarction 480 (9.6) 703 (15.2) 559 (9.2) <0.001
Coronary revascularization 447 (9.0 617 (13.4) 515 (8.5) <0.001
Stroke 137 (2.7) 231 (5.0) 145 (2.4) <0.001
Carotid revascularization 250 (5.0) 308 (6.7) 298 (4.9) <0.001
Ulcer/gangrene/amputation 158 (3.2) 217 (4.7) 181 (3.0) <0.001
Lower limb revascularization 122 (2.4) 171 (3.7) 157 (2.6) <0.001
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Table 3. Cont.
Variables T1 T2 T3 p-Value
Comorbidities n (%)
Any 756 (15.2) 1261 (27.3) 770 (12.7) <0.001
COPD 167 (3.3) 322 (7.0) 185 (3.1) <0.001
Chronic liver disease 385 (7.7) 570 (12.3) 406 (6.7) <0.001
Cancer 276 (5.5) 504 (10.9) 251 (4.2) <0.001
HbA1c = haemoglobin A1c; T1 = HbA1c on-target (≤0.5% below or above personalized goal); T2 = HbA1c below-target
(>0.5% below personalized goal); T3 = HbA1c above-target (>0.5% above personalized goal); BMI = body mass
index; HDL = high-density lipoprotein; LDL = low-density lipoprotein; BP = blood pressure; ACE-I = angiotensin
converting enzyme inhibitor; ARB = angiotensin receptor blocker; eGFR = estimated glomerular filtration rate; DKD
= diabetic kidney disease; DR = diabetic retinopathy; CVD = cardiovascular disease; COPD = chronic obstructive
pulmonary disease.






Model 1 Model 2
HR 95% CI p-Value HR 95% CI p-Value HR 95% CI p-Value
T1 (ref) 1.00 - <0.001 1.00 - <0.001 1.00 - <0.001
T2 1.54 1.31–1.82 <0.001 1.49 1.26–1.75 <0.001 1.08 0.92–1.28 0.34
T3 1.11 0.92–1.33 0.290 1.14 0.94–1.37 0.19 1.21 1.01–1.46 0.04
Cox proportional hazards regression according to HbA1c target categories plus use of agents causing hypoglycaemia,
unadjusted and adjusted for CVD risk factors (model 1) and complications/comorbidities (model 2). HRs (95%
CI) for mortality are shown for each HbA1c target category. HbA1c = haemoglobin A1c; HR = hazard ratio; CI =
confidence interval; T1 = HbA1c on-target (≤0.5% below or above personalized goal); T2 = HbA1c below-target
(>0.5% below personalized goal); T3 = HbA1c above-target (>0.5% above personalized goal).
4. Discussion
This analysis of individuals with type 2 diabetes from the RIACE cohort provides evidence that
achieving HbA1c levels close to normal values (i.e., <6.5%) is not associated with increased mortality,
unless patients are on treatment with drugs causing hypoglycaemia. These finding are consistent
with the positive relationship between severe hypoglycaemia and increased mortality reported in
the ACCORD [9], ADVANCE [10], and VADT [11] and with the observation that, in the ACCORD,
risk of death was higher in the intensive than in the conventional group only in patients requiring
more aggressive treatment, including insulin, because of little or no decrease in HbA1c following
treatment initiation [12]. However, unmeasured factors other than hypoglycaemia may be involved in
the increased mortality in patients on treatment with agents causing hypoglycaemia, including poor
adherence, depression, cognitive impairment, education, socio-economic status, etc. The results of our
study are also consistent with the increased mortality reported in older people with type 2 diabetes
from the Fremantle Diabetes Study Phase II who were treated with sulfonylurea and/or insulin and
had HbA1c levels < 7.0%, but not with the increased mortality observed in those who were treated
with metformin and had HbA1c levels < 6.5%, a finding which the authors attributed to confounding
by indication [20]. Conversely, our data are in contrast with previous reports from the UK General
Practice Research Database [21] and the Kaiser Permanente Diabetes Registry of Northwest [22] and
Northern California [23] showing a U-shape relationship between achieved HbA1c and mortality in
diabetic individuals, with both higher and lower HbA1c values associated with increased all-cause
mortality. However, Currie et al. analysed patients whose treatment had been intensified from
oral monotherapy to combination therapy with oral agents or to regimens that included insulin;
in addition, those with lower mean HbA1c levels were older and had worse renal function than
those with higher mean HbA1c values [21]. Indeed, the 2008 American Diabetes Association (ADA)
guidelines recommended less stringent HbA1c goals when the incremental but small benefit from
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lowering HbA1c from 7.0% to 6.0% [24,25] may be outweighed by the increased risk of hypoglycaemia
and the great effort required to achieve near-normoglycaemia [26]. Subsequently, based on the results
of the ACCORD [3], ADVANCE [4], and VADT [5], the 2012 Position Statement of the ADA and the
European Association for the Study of Diabetes recommended a patient-centred approach with setting
of personalized HbA1c goals according to several potential risks of adverse treatment effects [8].
When patients from the RIACE cohort were arbitrarily assigned to five different HbA1c goals
(from <6.5% to <8.5%) according the number (0 to 4) of potential risks among age > 70 years, diabetes
duration >10 years, presence of advanced complication and severe comorbidities, 44.8% of patients
were reclassified to a higher target, whereas 24.6% of patients were reclassified to a lower target than
the general goal of <7.0%. As a consequence, the proportion of individuals with HbA1c values less than
the personalized goal (61.4%) was higher than that of patients with HbA1c values less than the general
< 7.0% goal (40.2%) and much higher than that of patients meeting the more stringent HbA1c goal of
<6.5% (23.3%), consistent with previous reports from the National Health and Nutrition Examination
Survey (NHANES) [27,28]. In addition, about half of the RIACE participants with HbA1c levels less
than their personalized goal (29.5% of the whole cohort) were well below this threshold (i.e., >0.5%),
as the personalized goal for the majority of them was higher than the general < 7.0% goal which was
recommended at the time patients underwent baseline evaluation (i.e., in the years 2006–2008). These
findings are consistent with a cross-sectional analysis of the data from older (≥65 years) NHANES
participants with diabetes from 2001 through 2010, which showed that a substantial proportion of
patients were potentially overtreated, i.e., had an HbA1c < 7.0% irrespective of health status and type of
treatment, with no change over the 10-year study period [29]. In addition, a cross-sectional analysis of
42,669 outpatients with type 2 diabetes from the Diabetes Collaborative Registry showed that one-fourth
were tightly controlled with medications that confer a high risk of hypoglycaemia, thus suggesting
potential overtreatment of a substantial proportion of people [30]. Finally, a retrospective cohort study
using data from the US Veterans Health Administration showed that only one-fourth of the older
patients whose treatment resulted in very low levels of HbA1c or BP underwent de-intensification of
anti-hyperglycaemic or anti-hypertensive therapy [31].
The most intriguing and original finding of our study is that below-target patients showed a
mortality risk higher than that of on-target individuals (i.e., with HbA1c values ≤ 0.5% below or above
their personalized goal) and similar to that of individuals above-target (i.e., with HbA1c values >
0.5% above their personalized goal). Excess risk was observed in the whole cohort and in patients
on treatment with anti-hyperglycaemic drugs causing hypoglycaemia, but not in patients not treated
with these agents, and was attenuated, though not completely in those on “hypoglycaemic” agents,
after adjusting for CVD risk factors and the potential risks considered for patients’ stratification into
target categories.
Our findings that, in patients on treatment with agents causing hypoglycaemia, HbA1c values
< 6.5% or ≥0.5% less than the personalized goal are associated with increased mortality risk have
important implications for clinical practice. First, these data support the importance of setting a
personalized HbA1c range rather than an upper HbA1c threshold (e.g., 7.0–7.5% instead of <7.5%) when
the use of agents causing hypoglycaemia is required for achieving the glycaemic goal. This approach
would be in line with that adopted by the recent guidelines of the European Society of Cardiology
(in collaboration with the European Association for the Study of Diabetes (EASD)) for the treatment
of hypertension in diabetic patients, which recommend a systolic BP goal of <130 mmHg, but not
<120 mmHg, in younger individuals and of <140 mmHg, but not <130 mmHg, in older individuals and
a diastolic BP goal of <80 mmHg, but not <70 mmHg in all patients [32]. Second, our results provide
further support to the current guideline recommendations to set higher glycaemic goals when the
risks of lower HbA1c targets may outweigh the potential benefits and to modify the treatment regimen
accordingly [33]. Treatment modification may include de-intensification of pharmacologic therapy
with drugs causing hypoglycaemia in patients with HbA1c levels well below the individual HbA1c goal.
At the time patients underwent baseline evaluation, only a few therapeutic options (i.e., metformin,
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pioglitazone, and acarbose) were available in addition to insulin and insulin secretagogues which,
therefore, were used by a substantial proportion of the RIACE participants (62.8%). However, during
the last few decades, several new classes of anti-hyperglycaemic agents that do not cause hypoglycaemia
have been made available, possibly allowing more stringent HbA1c goals even in high-risk patients,
provided that combination therapy with insulin and/or insulin secretagogues is not required for
achieving these targets.
The strengths of this study include the large size of the cohort, the analysis of a contemporary
real-life dataset, the assessment of a wide range of clinical parameters, and the completeness of baseline
and follow-up data. However, this study has several limitations. First, the analysis is based on baseline
HbA1c levels and treatments, which have likely changed during the follow-up for several reasons,
including disease progression, guideline change, and availability of new drugs, the use of which was
however very limited at the time of the census. Second, no data are available on the number and
severity of hypoglycaemic episodes as well as on individual attitude and expected treatment efforts
and resources and support systems. Third, the score (0 to 4) used for personalized HbA1c goals may
not mirror the severity of complications and comorbidities, as it does not distinguish one complication
or comorbidity from another and individuals with one or multiple complications or comorbidities.
Fourth, the study findings may not be applicable to the general ambulatory diabetes population, as
only part of the individuals with type 2 diabetes attend tertiary referral outpatients Diabetes Clinics in
Italy. Fifth, the observational design makes causal interpretation impossible. Sixth, there are potential
methodological limitations, which have been extensively addressed in previous RIACE reports [13–19].
5. Conclusions
This analysis of the RIACE cohort indicates that near-normal HbA1c levels or HbA1c values well
below the personalized goal are associated with an increased risk of death only if achieved with the use
of agents causing hypoglycaemia. These findings support the importance of avoiding overtreatment
with these drugs in high-risk individuals by setting both upper and lower personalized HbA1c goals
and of using anti-hyperglycaemic agents that do not cause hypoglycaemia for safely achieving more
stringent HbA1c goals.
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